deltatrials
Completed PHASE3 NCT00286091

Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer

Sponsor: Amgen

Conditions Hormone Refractory Prostate Cancer
Interventions Denosumab Placebo
Updated 7 times since 2017 Last updated: Sep 20, 2018 Started: Jan 24, 2006 Primary completion: Jul 30, 2010 Completion: Apr 9, 2014

Listed as NCT00286091, this PHASE3 trial focuses on Hormone Refractory Prostate Cancer and remains completed. Sponsored by Amgen, it has been updated 7 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Nov 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jun 2018 — Nov 2018 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Amgen
Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.